Anders Nykjaer
Gründer bei Insusense ApS
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mads Fuglsang Kjølby | M | - |
Insusense ApS
 Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | - |
| Paul B. Little | M | - |
Insusense ApS
Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark. | 20 Jahre |
| Karl Anker Jørgensen | M | 69 |
University of Aarhus
| - |
| Connie Hedegaard Koksbang | F | 63 |
University of Aarhus
| 7 Jahre |
| Lars Henrik Fugger | M | 64 |
University of Aarhus
| 28 Jahre |
| Michael Christiansen | M | 79 |
University of Aarhus
| - |
| Finn Skou Pedersen | M | - |
University of Aarhus
| - |
| Mogens Ryttergård Duch | M | - |
University of Aarhus
| - |
| Karl Møller Bek | M | - |
University of Aarhus
| - |
| Sara Fevre Kindberg | M | - |
University of Aarhus
| - |
| Jesper Zeuthen | M | - |
University of Aarhus
| - |
| Jon Steen Petersen | M | 77 |
University of Aarhus
| - |
| Claus Vastrup | M | 82 |
University of Aarhus
| - |
| Børge Obel | M | 76 |
University of Aarhus
| 20 Jahre |
| Jens Christian Jensenius | M | 82 |
University of Aarhus
| - |
| Henrik Kagenow | M | - |
University of Aarhus
| - |
| Peder Tuborgh | M | 61 |
University of Aarhus
| - |
| Brian Bech Nielsen | M | 66 |
University of Aarhus
| 36 Jahre |
| Carsten Bjerg | M | 64 |
University of Aarhus
| - |
| Nina Smith | F | 68 |
University of Aarhus
| - |
| Caroline Søeborg Ahlefeldt-Laurvig-Bille | F | - |
University of Aarhus
| 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Thomas E. Willnow | M | - |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | 9 Jahre |
| Henrik Andersen | M | 56 |
University of Aarhus
| 9 Jahre |
| Gian Luca Cattani | M | 55 |
University of Aarhus
| 4 Jahre |
| Rune Róin | M | - |
University of Aarhus
| 5 Jahre |
| Karsten Breum | M | 51 |
University of Aarhus
| 4 Jahre |
| Mikael Andreas Geday | M | 56 |
University of Aarhus
| 7 Jahre |
| Dorthe Berntsen | M | 62 |
University of Aarhus
| 5 Jahre |
| Martin Lippert | M | 57 |
University of Aarhus
| 5 Jahre |
| Jim Snabe | M | 58 |
University of Aarhus
| 6 Jahre |
| Etienne Adriansen | M | 60 |
University of Aarhus
| 5 Jahre |
| Kristian Villumsen | M | 54 |
University of Aarhus
| 1 Jahre |
| Poul Jagd Mogensen | M | - |
University of Aarhus
| 3 Jahre |
| Jørgen Rønnow | M | - |
University of Aarhus
| 1 Jahre |
| Lucy Lu Li Dahlgren | F | 55 |
University of Aarhus
| 4 Jahre |
| Anders Lund | M | 51 |
University of Aarhus
| 4 Jahre |
| Erik Dudman Nielsen | M | - |
University of Aarhus
| 1 Jahre |
| Peter Baekgaard | M | - |
University of Aarhus
| 5 Jahre |
| Line Christa Amanda Sørensen | F | 49 |
University of Aarhus
| 3 Jahre |
| Thomas Dalsgaard | M | 58 |
University of Aarhus
| 6 Jahre |
| Jesper Ejlersen | M | 57 |
University of Aarhus
| 1 Jahre |
| Merete Vangsøe Simonsen | F | 57 |
University of Aarhus
| 3 Jahre |
| Otto Frederik Spliid | M | 63 |
University of Aarhus
| 3 Jahre |
| Carsten Fensholt | M | 62 |
University of Aarhus
| 4 Jahre |
| Kurt Bligaard Pedersen | M | 65 |
University of Aarhus
| 1 Jahre |
| Marina Lønning | F | 56 |
University of Aarhus
| 1 Jahre |
| John Petersen | M | - |
University of Aarhus
| 6 Jahre |
| Dorte Wigg | F | - |
University of Aarhus
| 3 Jahre |
| Anders Svenningsen | M | - |
University of Aarhus
| 6 Jahre |
| John Sommer Schmidt | M | 51 |
University of Aarhus
| 4 Jahre |
| Tina Høgsted Svanberg | F | - |
University of Aarhus
| 4 Jahre |
| Mogens Thorninger | M | - |
University of Aarhus
| 5 Jahre |
| Tommy Jensen | M | - |
University of Aarhus
| 2 Jahre |
| Marianne Søgaard | F | 56 |
University of Aarhus
| 3 Jahre |
| Ulrik Thagesen | M | 53 |
University of Aarhus
| 1 Jahre |
| Michael Hannibal | M | 55 |
University of Aarhus
| 3 Jahre |
| Casper Blaase Johansen | M | 49 |
University of Aarhus
| 4 Jahre |
| Preben Vinkler Lindgaard | M | 56 |
University of Aarhus
| 1 Jahre |
| Stenkil Ole | M | 51 |
University of Aarhus
| 5 Jahre |
| Ricco Larsen | M | - |
University of Aarhus
| 6 Jahre |
| Søren Elmann Ingerslev | M | - |
University of Aarhus
| 3 Jahre |
| Milan Zdravkovic | M | 54 |
University of Aarhus
| 7 Jahre |
| Morten Kierkegaard | M | 54 |
University of Aarhus
| 1 Jahre |
| Lars Green | M | 57 |
University of Aarhus
| 1 Jahre |
| Ulf Roger Tossman | M | 68 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Jørn Enggaard | M | - |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Klaus Pedersen | M | 57 |
University of Aarhus
| 1 Jahre |
| Palle Schelde Jensen | M | - |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Alex Haahr Gouliaev | M | 58 |
University of Aarhus
| 3 Jahre |
| Mads Nipper | M | 58 |
University of Aarhus
| 2 Jahre |
| Hans-Henrik Horsted Eriksen | M | 64 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Steen Helde Hemmingsen | M | 80 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Morten Brøgger | M | 55 |
University of Aarhus
| 1 Jahre |
| Kristian Johnsen Hundebøll | M | 58 |
University of Aarhus
| 4 Jahre |
| Kaare Heinsen | M | - |
University of Aarhus
| 4 Jahre |
| Jørgen Jensen | M | 56 |
University of Aarhus
| 1 Jahre |
| Mikael Vissing Jakobsen | M | - |
University of Aarhus
| 4 Jahre |
| Torbjørn Bjerke | M | 61 |
University of Aarhus
| 6 Jahre |
| Hans Jacob Carstensen | M | 59 |
University of Aarhus
| 2 Jahre |
| René Schneider | M | 51 |
University of Aarhus
| 6 Jahre |
| Anders Pedersen | M | 64 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | 3 Jahre |
| Flemming Besenbacher | M | 71 |
University of Aarhus
| 3 Jahre |
| Jan Anders Vedin | M | 82 |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects. | - |
| Henrik Nørremark | M | 58 |
University of Aarhus
| 4 Jahre |
| Henrik Poulsen | M | 57 |
University of Aarhus
| 1 Jahre |
| Lars Fruergaard Jorgensen | M | 58 |
University of Aarhus
| 1 Jahre |
| Allan Viggo Tornøe Nørholm | M | 58 |
University of Aarhus
| 1 Jahre |
| Henriette Schütze | F | 56 |
University of Aarhus
| 1 Jahre |
| Søren Steen Pedersen | M | - |
University of Aarhus
| 2 Jahre |
| Holger Jon Møller | M | - |
University of Aarhus
| 3 Jahre |
| Jørgen Michael Christensen | M | 74 |
University of Aarhus
| 3 Jahre |
| Ole Christian Anthon Christiansen | M | 67 |
University of Aarhus
| 1 Jahre |
| Jakob Bardram | M | 56 |
University of Aarhus
| 3 Jahre |
| Louis Illum Honoré | M | 62 |
University of Aarhus
| 4 Jahre |
| Henrik Dalbøge | M | 67 |
University of Aarhus
| 3 Jahre |
| Niels Hobolt | M | - |
University of Aarhus
| 1 Jahre |
| Carsten Tirsbæk Madsen | M | 61 |
University of Aarhus
| 1 Jahre |
| Steffen B. Petersen | M | - |
University of Aarhus
| 5 Jahre |
| Peter Marner Åge Jacobsen | M | 61 |
University of Aarhus
| 1 Jahre |
| Lars Lose | M | - |
University of Aarhus
| 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Dänemark | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Anders Nykjaer
- Persönliches Netzwerk